Abstract
Introduction A recent World Health Organization report states that at least 40% of all cancer cases may be preventable, with smoking, alcohol consumption and obesity identified as three of the most important modifiable lifestyle factors. Established risk factors for head and neck cancer include tobacco use, alcohol consumption and human papillomavirus infection. Given the significant decline in smoking rates, particularly within developing countries, other potentially modifiable risk factors warrant investigation. Obesity and related metabolic disorders such as type 2 diabetes and hypertension have all been associated with head and neck cancer risk in multiple observational studies. However, obesity has also been correlated with other major head and neck cancer risk factors such as smoking, meaning independent effects are difficult to establish. Furthermore, selection bias, confounding or reverse causality may explain the findings from observational studies.
Methods To overcome the challenges of observational studies, we conducted two-sample Mendelian randomization (inverse variance weighted (IVW) method) using genetic variants which were robustly associated with obesity, T2D and hypertension in genome-wide association studies (GWAS). Outcome data was taken from the largest available GWAS of 6,034 oral and oropharyngeal cases, with 6,585 controls.
Results We found limited evidence of a causal effect of genetically proxied body mass index (OR IVW 0.89, 95%CI 0.72–1.09, p = 0.26 per 1 SD in BMI (4.81 kg/m2)) on combined oral and oropharyngeal cancer risk. Similarly, there was limited evidence for genetically-proxied T2D (OR IVW 0.92, 95%CI 0.84–1.01, p = 0.09 per 1-log unit higher odds of T2D), or related traits including fasting glucose and insulin. Higher HbA1c resulted in a weak protective effect on combined oral and oropharyngeal cancer risk (OR IVW 0.56, 95%CI 0.32–1.00, p = 0.05 per 1-log-unit % higher HbA1c), which was not robust to sensitivity testing. Finally, there was limited evidence for an effect of systolic blood pressure on combined oral and oropharyngeal cancer risk (OR IVW 1.00, 95%CI 0.97–1.03, p = 0.89 per 1 unit mmHg increase). Smoking also appears to act as a mediator in the relationship between obesity and HNC in instrument-risk factor analyses.
Conclusion This analysis suggests the possibility that the effect of metabolic disorders may have been previously overestimated in observational studies. However, these cannot be directly compared given the differences in methodologies and the interpretation of estimates.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
M.G. was a National Institute for Health Research (NIHR) academic clinical fellow and is currently supported by a Wellcome Trust GW4-Clinical Academic Training PhD Fellowship. This research was funded in part, by the Wellcome Trust [Grant number 220530/Z/20/Z]. For the purpose of open access, the author has applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission. R.C.R. is a de Pass VC research fellow at the University of Bristol. J.T. is supported by an Academy of Medical Sciences (AMS) Springboard award, which is supported by the AMS, the Wellcome Trust, Global Challenges Research Fund (GCRF), the Government Department of Business, Energy and Industrial strategy, the British Heart Foundation and Diabetes UK (SBF004\1079). A.R.N. was supported by the National Institute for Health Research (NIHR) Bristol Biomedical Research Centre which is funded by the National Institute for Health Research (NIHR) and is a partnership between University Hospitals Bristol NHS Foundation Trust and the University of Bristol. Department of Health and Social Care disclaimer: The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care. This publication presents data from the Head and Neck 5000 which contributes to international VOYAGER and HEADSpAcE head and neck cancer consortia. The Head and Neck 5000 study was a component of independent research funded by the National Institute for Health Research (NIHR) under its Programme Grants for Applied Research scheme (RP-PG-0707-10034). The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. Core funding was also provided through awards from Above and Beyond, University Hospitals Bristol and Weston Research Capability Funding and the NIHR Senior Investigator award to A.R.N. Human papillomavirus (HPV) serology was supported by a Cancer Research UK Programme Grant, the Integrative Cancer Epidemiology Programme (C18281/A20919). The VOYAGER study was supported in part by the US National Institute of Dental and Craniofacial Research (NIDCR; R01 DE025712). The genotyping of the HNC cases and controls was performed at the Center for Inherited Disease Research (CIDR) and funded by the US National Institute of Dental and Craniofacial Research (NIDCR; 1X01HG007780-0). E.E.V, C.B. and D.L. are supported by Diabetes UK (17/0005587). E.E.V, and C.B. are supported by the World Cancer Research Fund (WCRF UK), as part of the World Cancer Research Fund International grant programme (IIG_2019_2009). M.G., T.D., G.D.S, E.E.V., R.C.R, and C.B. are part of the Medical Research Council Integrative Epidemiology Unit at the University of Bristol supported by the Medical Research Council (MC_UU_00011/1, MC_UU_00011/5, MC_UU_00011/6, MC_UU_00011/7).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study used only openly available summary-level human data. Analysis was conducted using publicly available GWAS data as cited. Full summary statistics for the GAME-ON outcome data GWAS can be accessed via dbGAP (OncoArray: Oral and Pharynx Cancer; study accession number: phs001202.v1.p1, August 2017 at: https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001202.v1.p1). There is one selected publication by Lesseur et al. related to this data. Exposure data is publicly available from the relevant studies and via the IEU Open GWAS (https://gwas.mrcieu.ac.uk/). MR analyses were conducted using the TwoSampleMR package in R (version 3.5.3). A copy of the code and all files used in this analysis is available at GitHub (https://github.com/MGormley12/metabolic_trait_hnc_mr.git).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵§ Joint senior authors
Data Availability
Summary-level analysis was conducted using publicly available GWAS data as cited. Full summary statistics for the GAME-ON outcome data GWAS can be accessed via dbGAP (OncoArray: Oral and Pharynx Cancer; study accession number: phs001202.v1.p1, August 2017 at: https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001202.v1.p1). There is one selected publication by Lesseur et al. related to this data. Exposure data is publicly available from the relevant studies and via the IEU Open GWAS (https://gwas.mrcieu.ac.uk/). MR analyses were conducted using the TwoSampleMR package in R (version 3.5.3). A copy of the code and all files used in this analysis is available at GitHub (https://github.com/MGormley12/metabolic_trait_hnc_mr.git).
https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001202.v1.p1
